New Amylin Drug Petrelintide Delivers 10% Weight Loss With Half the GI Side Effects of GLP-1s
Phase II trial shows petrelintide, a weekly amylin injectable, achieves meaningful weight loss with far fewer nausea and vomiting events than GLP-1 drugs.
Summary
A new investigational weight-loss drug called petrelintide showed promising results in a global phase II trial. The weekly self-injected drug, an amylin analog, helped people with obesity or overweight lose roughly 9–11% of their body weight over 42 weeks when combined with diet and exercise. Crucially, it caused significantly fewer gastrointestinal side effects than GLP-1 drugs like semaglutide — roughly half the rates of nausea and vomiting. Researchers suggest it could become a first-line obesity treatment in primary care settings, particularly for patients who don't need the cardiovascular or liver-specific benefits that GLP-1s offer. The drug works through a different brain pathway than GLP-1s, raising the possibility of combining both drug classes for additive effects.
Detailed Summary
Obesity pharmacotherapy is expanding beyond GLP-1 receptor agonists, and a new class of drug may offer a more tolerable option for the majority of patients who need moderate rather than dramatic weight loss. Petrelintide, a long-acting amylin analog administered once weekly by injection, demonstrated significant and sustained weight reduction in the ZUPREME-1 phase II trial presented at the 2026 American Diabetes Association Scientific Sessions in New Orleans.
In the trial, all five investigational doses of petrelintide produced significantly greater weight loss than placebo by week 28, with losses ranging from 8.7% to 10.7% sustained through a 42-week maintenance phase, compared to just 1.7% in the placebo group. Lead investigator Dr. W. Timothy Garvey of the University of Alabama at Birmingham emphasized that this level of weight loss is clinically meaningful for most obesity patients and avoids the risks of excessive loss including malnutrition and adverse body composition changes.
The drug's tolerability profile is a standout feature. Diarrhea rates matched placebo exactly (7.4%), vomiting was actually lower with petrelintide (3.0% vs 6.2%), and drug discontinuation due to adverse events was very low at 4.5% — roughly half or less of rates seen in GLP-1 trials. Nausea occurred in 19.6% of petrelintide users versus 6.2% on placebo, but 77% of GI events were mild overall.
Amylin is a hormone secreted by pancreatic beta cells that signals satiety and appetite control in the brain via receptors distinct from GLP-1 pathways. This difference opens the door to potential combination therapy, where amylin and GLP-1 drugs could work additively with potentially differentiated side effect profiles.
Garvey suggested petrelintide may be especially well-suited for primary care use and for patients without obesity-related complications like heart disease or liver disease, where GLP-1s currently have clearer evidence. Petrelintide remains investigational; larger phase III trials and long-term safety data are still needed before clinical adoption.
Key Findings
- Petrelintide achieved 8.7–10.7% body weight loss sustained over 42 weeks across all five dose groups tested.
- GI side effects were roughly half those seen in GLP-1 trials; diarrhea rates matched placebo exactly.
- Drug discontinuation due to adverse events was very low at 4.5%, well below GLP-1 trial benchmarks of 5–10%.
- Amylin binds different brain receptors than GLP-1s, suggesting additive potential when drugs are combined.
- Researchers propose petrelintide as a candidate first-line obesity treatment in primary care for uncomplicated cases.
Methodology
This is a meeting coverage news report from MedPage Today summarizing phase II randomized controlled trial data (ZUPREME-1) presented at the 2026 ADA Scientific Sessions. The source is a credible medical news outlet; findings are based on conference-presented RCT data, though full peer-reviewed publication is not yet confirmed.
Study Limitations
Phase II data presented at a conference may differ from final peer-reviewed published results; long-term safety beyond 42 weeks is unknown. The article does not report full statistical details, confidence intervals, or dose-specific breakdowns. Phase III trials are needed before regulatory approval or broad clinical recommendations can be made.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.